Amount of Funding. In consideration of MTI's performance of its obligations under the Research Program, (a) Sankyo paid, or in the case of the third year will pay, MTI a research fee ofUS$3,500,000 for each of the first three Research Years during the term of the Research Program, and (b) Sankyo shall pay a research fee ofUS$3,500,000 for the fourth Research Year during the term of the Research Program.
Appears in 2 contracts
Samples: Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc), Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)
Amount of Funding. In consideration of MTI's performance of its obligations under the Research Program, (a) Sankyo paid, or in the case of the third year will pay, paid MTI a research fee ofUS$3,500,000 of US$3,500,000 for each of the first three four Research Years during the term of the Research Program, Program and (b) Sankyo shall pay a research fee ofUS$3,500,000 of US$3,500,000 for the fourth fifth Research Year during the term of the Research Program.
Appears in 2 contracts
Samples: Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc), Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)
Amount of Funding. In consideration of MTI's performance of its obligations under the Research Program, (a) Sankyo paid, or in the case of the third year will pay, paid MTI a research fee ofUS$3,500,000 of US$3,500,000 for each of the first three two Research Years during the term of the Research Program, and (b) Sankyo shall pay a research fee ofUS$3,500,000 of US$3,500,000 for the fourth third Research Year during the term of the Research Program, of which US$1,750,000 remains outstanding.
Appears in 2 contracts
Samples: Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc), Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)